U.S. markets closed
  • S&P Futures

    3,826.75
    +1.25 (+0.03%)
     
  • Dow Futures

    30,950.00
    +17.00 (+0.05%)
     
  • Nasdaq Futures

    11,679.25
    +5.00 (+0.04%)
     
  • Russell 2000 Futures

    1,739.10
    +0.80 (+0.05%)
     
  • Crude Oil

    111.11
    -0.65 (-0.58%)
     
  • Gold

    1,823.20
    +2.00 (+0.11%)
     
  • Silver

    20.78
    -0.03 (-0.12%)
     
  • EUR/USD

    1.0533
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    3.2060
    +0.0120 (+0.38%)
     
  • Vix

    28.36
    +1.41 (+5.23%)
     
  • GBP/USD

    1.2204
    +0.0019 (+0.16%)
     
  • USD/JPY

    136.0320
    -0.0960 (-0.07%)
     
  • BTC-USD

    20,360.76
    -226.08 (-1.10%)
     
  • CMC Crypto 200

    441.41
    -8.65 (-1.92%)
     
  • FTSE 100

    7,323.41
    +65.09 (+0.90%)
     
  • Nikkei 225

    26,748.38
    -301.09 (-1.11%)
     

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market to Surpass US$ 20,450.6 Million by 2030 - Coherent Market Insights

·6 min read

SEATTLE, June 22, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global acute bacterial skin and skin structure infections (ABSSSI) market is estimated to be valued at US$ 10,263.5 million in 2022 and is expected to exhibit a CAGR of 9.0% over the forecast period (2022-2030).

Coherent_Market_Insights_Logo
Coherent_Market_Insights_Logo

Key Trends and Analysis of the Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market:

Key trends in market include widespread presence of acute bacterial skin and skin structure infections (ABSSSI); increasing approval of novel drugs for acute bacterial skin and skin structure infections (ABSSSI), and increasing collaborations, acquisitions, and partnerships among key players. These key trends are expected to aid in growth of the global acute bacterial skin and skin structure infections (ABSSSI) market.

According to an article published in the PLOS One journal, a peer-reviewed open access scientific journal in July 2020, the lifetime prevalence of skin and soft tissue infections (SSTI), a type of ABSSSI in people who inject drugs (PWID) in London was found to be 64% (abscess and/or cellulitis), on the basis of data collected between October 2017 and March 2019.

Moreover, rapid research and development in the field of acute bacterial skin and skin structure infections (ABSSSI) for development of novel treatment for the same is expected to fuel market growth over the forecast period. For instance, in January 2022, Paladin Labs Inc., a subsidiary of Endo International plc launched Xydalba (dalbavancin for injection), in Canada. Xydalba is a 30-minute intravenous (IV) therapy, which can be administered as a single- or two-dose regimen for treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.

Furthermore, key players operating in the global acute bacterial skin and skin structure infections (ABSSSI) market are focusing on adoption of inorganic growth strategies such as partnerships, acquisitions, collaborations, and others in order to expand their market presence in the global market. For instance, in May 2020, Advanz Pharma, a U.K.-based pharmaceutical company, announced that it had completed the acquisition of Correvio Pharma Corp., a Canada-based specialty pharmaceutical company whose product portfolio includes licensed medicines such as XYDALBA (dalbavancin hydrochloride) indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1531

Key Market Takeaways:

Global acute bacterial skin and skin structure infections (ABSSSI) market is expected to exhibit a CAGR of 9.0% over the forecast period, owing to rising focus of market players on regulatory approvals for novel acute bacterial skin and skin structure infections (ABSSSI) therapeutics. For instance, in July 2021, AbbVie Inc. ., a U.S. based pharmaceutical company announced that it has received the U.S. Food and Drug Administration (USFDA) approval for its drug Dalvance (dalbavancin), administered as an intravenous (IV) infusion for the treatment of pediatric patients with ABSSSI caused by methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.

Among infection type, community acquired ABSSSI segment is expected to account for the largest market share in 2022, owing to rising drug launches by market players for treatment of community acquired acute bacterial skin and skin structure infections (ABSSSI). For instance, in February 2021, Paratek Pharmaceuticals, Inc., a U.S.-based pharmaceutical company announced that it is expanding commercial launch of its tetracycline-class oral antibiotic Nuzyra (omadacycline) into the community setting. Nuzyra is indicated for the treatment of adults with acute skin and skin structure infections (ABSSSI).

Key players operating in the global acute bacterial skin and skin structure infections (ABSSSI) market include Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Arrevus, Inc., AbbVie, Inc., Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Accord Healthcare Ltd., Intas Pharmaceuticals Ltd., Fresenius SE & Co. KGaA, Sandoz Inc., Glenmark Pharmaceuticals Ltd, and Cadila Healthcare Ltd.

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1531

Detailed Segmentation:

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Drug Type:

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Infection Type:

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Route of Administration:

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Distribution Channel:

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Region:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/1531

Find related trending report below:

North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, by Drug Type (Oral & Parenteral Antibiotics (Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, and Others) and Topical Antibiotics (Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, and Povidone-Iodine)), by Infection Type (Hospital Acquired ABSSSI and Community Acquired ABSSSI), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, and Europe) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com 
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedInTwitter

Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg

 

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/acute-bacterial-skin-and-skin-structure-infections-absssi-market-to-surpass-us-20-450-6-million-by-2030--coherent-market-insights-301573018.html

SOURCE Coherent Market Insights